Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study
2011
Abstract Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1mo at the lumbar spine, total hip, and trochanter (all p p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
38
Citations
NaN
KQI